Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: Anticipated consequences and initial responses
- PMID: 32445265
- PMCID: PMC7283853
- DOI: 10.1111/dar.13079
Illicit drug use and harms in Australia in the context of COVID-19 and associated restrictions: Anticipated consequences and initial responses
Conflict of interest statement
PMD has received investigator‐driven funding from Gilead Sciences in relation to work on hepatitis C and an untied educational grant from Indivior for work unrelated to this study. AP has received investigator‐driven untied funding from Mundipharma and Seqirus for work unrelated to this study. PMD is a National Health and Medical Research Council Senior Research Fellow, and AP is a National Health and Medical Research Council Emerging Leader. These funders had no input into any aspect of this study. PMD has served as an unpaid member on Mundipharma's Advisory Board around the Nyxoid intranasal naloxone product. The authors gratefully acknowledge the support of the Victorian Operational Infrastructure Support Fund.
References
-
- Australian Criminal Intelligence Commission . Illicit drug data report. Canberra, Australia: Australian Criminal Intelligence Commission, 2019.
-
- Degenhardt L, Day C, Dietze P et al Effects of a sustained heroin shortage in three Australian states. Addiction 2005;100:908–20. - PubMed
-
- Dietze P, Fitzgerald J. Interpreting changes in heroin supply in Melbourne: droughts, gluts or cycles? Drug Alcohol Rev 2002;21:295–303. - PubMed
-
- Moore TJ, Caulkins JP, Ritter A, Dietze P, Monagle S, Pruden J. Heroin markets in Australia: current understandings and future possibilities. Fitzroy: Turning Point Alcohol and Drug Centre, 2005.
